𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells

✍ Scribed by Branch, P; Masson, M; Aquilina, G; Bignami, M; Karran, P

Book ID
110063991
Publisher
Nature Publishing Group
Year
2000
Tongue
English
Weight
187 KB
Volume
19
Category
Article
ISSN
0950-9232

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Mechanism of resistance to cisplatin in
Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53
✍ Faina Vikhanskaya; Luana Clerico; Monica Valenti; Maria S. Stanzione; Massimo Br πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 99 KB πŸ‘ 2 views

A possible novel mechanism of cross-resistance to cisplatin (CDDP) in the doxorubicin-resistant ovarian-cancer cell line A2780-DX3, which displays atypical multidrug resistance, is presented. A2780-DX3 is found to be more resistant than the parental line A2780 in terms of CDDP-induced cytotoxicity a

Role of ERCC1 promoter hypermethylation
Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas
✍ Hua-Yun Chen; Cui-Jie Shao; Fu-Rong Chen; Aij-Lie Kwan; Zhong-Ping Chen πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 French βš– 523 KB

## Abstract Overexpression of ERCC1 mRNA is associated with drug resistance to cisplatin in human gliomas, but the role of the ERCC1 promoter in drug resistance has not been demonstrated. We have used sodium bisulfite sequencing to compare ERCC1 promoter methylation patterns in cisplatin‐sensitive

Akt promotes cisplatin resistance in hum
Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function
✍ Michael Fraser; Tao Bai; Benjamin K. Tsang πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 736 KB

## Abstract Resistance to cisplatin‐based chemotherapy is a major cause of treatment failure in human ovarian cancer. Wild‐type __TP53__ status is often, but not always, associated with cisplatin sensitivity, suggesting that additional factors may be involved. Overexpression/activation of the phosp